Commercialized artemisinin derivatives combined with colistin protect against critical Gram-negative bacterial infection

The emergence and spread of the mcr-1 gene and its mutants has immensely compromised the efficient usage of colistin for the treatment of drug-resistant Gram-negative bacterial infection in clinical settings. However, there are currently no clinically available colistin synergis. Here we identify ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Yonglin, Liu, Baichen, Chu, Xiuling, Su, Jianqing, Xu, Lei, Li, Li, Deng, Xuming, Li, Dan, Lv, Qianghua, Wang, Jianfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458715/
https://www.ncbi.nlm.nih.gov/pubmed/36076060
http://dx.doi.org/10.1038/s42003-022-03898-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458715/
https://www.ncbi.nlm.nih.gov/pubmed/36076060
http://dx.doi.org/10.1038/s42003-022-03898-5

Ejemplares similares